WO2020001203A1 - Solution d'injection de vitamine d'acide aminé composée et son utilisation - Google Patents

Solution d'injection de vitamine d'acide aminé composée et son utilisation Download PDF

Info

Publication number
WO2020001203A1
WO2020001203A1 PCT/CN2019/087884 CN2019087884W WO2020001203A1 WO 2020001203 A1 WO2020001203 A1 WO 2020001203A1 CN 2019087884 W CN2019087884 W CN 2019087884W WO 2020001203 A1 WO2020001203 A1 WO 2020001203A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
amino acid
injection
compound amino
acid vitamin
Prior art date
Application number
PCT/CN2019/087884
Other languages
English (en)
Chinese (zh)
Inventor
葛圣金
Original Assignee
复旦大学附属中山医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 复旦大学附属中山医院 filed Critical 复旦大学附属中山医院
Publication of WO2020001203A1 publication Critical patent/WO2020001203A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Definitions

  • the invention relates to the technical field of biomedicine, in particular to a compound amino acid vitamin injection and application thereof.
  • Amino acids are the basic unit of protein.
  • Compound amino acid injection as an intravenous nutritional agent, is widely used in nutritional support treatment.
  • the amino acid compound injection commonly known as compound amino acid injection (15HBC)
  • compound amino acid injection has a formula that contains 7.66 g of isoleucine and valine per 1000 ml.
  • Acid 8.86g leucine acid 4.00g, lysine 4.10g (lysine acetate 5.80g), arginine 5.80g, histidine 1.60g, methionine 2.50g, serine 3.30g, phenylpropyl Amino acid 3.20g, proline 6.30g, threonine 2.00g, glycine 3.30g, tryptophan 0.90g, L-cysteine hydrochloride ⁇ 0.20g.
  • the amino acid compound injection commonly called compound amino acid injection (18AA-II), has a formula of 1.98 g of leucine, 1.43 g of isoleucine, 1.83 g of valine, 4.08 g of alanine, and 250 ml per 250 ml.
  • Chinese patent 2012105433005 uses lactic acid as a pH regulator to reduce the pressure-reducing substance of injection solution after high temperature sterilization.
  • Chinese patent 2014102294531 discloses a pharmaceutical composition of compound amino acid injection (17AA-I), which is used for patients with insufficient protein intake, malabsorption and other amino acids that cannot meet the metabolic needs of the body, improving the nutritional status and metabolic properties of patients after surgery.
  • each 1000ml contains the main drug component: 0.696-1.05 g of L-isoleucine; 0.94-1.42 g of L-leucine; 1.11-1.68 g of L-lysine, or L -Lysine acetate 1.57-2.36 g; L-methionine or methionine 0.896-1.35 g; L-phenylalanine 0.82-1.24 g; L-threonine 0.896-1.35 g; L-color Glycine 0.34-0.52 g; L-arginine 2.315-3.48 g, or L-arginine acetate 3.11-4.61 g; L-valine 0.76-1.14 g; glycine 2.58-3.88 g; L-histidine 0.58-0.88 g; L-tyrosine 0.13-0.20 g; L-alanine 4.26-6.40 g; L-proline 2.32-3.48 g;
  • the invention aims at the characteristics of patients during perioperative anesthesia, and in accordance with the concept of accelerated rehabilitation surgery, develops a compound amino acid vitamin injection for inhibiting catabolism, promoting anabolic metabolism, and producing heat and heat, improving body energy metabolism and immune function, and accelerating The patient recovered.
  • a second object of the present invention is to provide the use of the compound amino acid vitamin injection as described above.
  • a compound amino acid vitamin injection wherein each 1000 ml of the injection contains a main drug component:
  • Vitamin B6 1-100mg
  • Vitamin B1 0-50mg
  • Vitamin B12 0-100 ⁇ g.
  • the main component of the injection solution per 1000 ml is: L-leucine: 20.6 g,
  • Vitamin B6 10mg
  • Vitamin B1 0mg
  • Vitamin B12 0 ⁇ g.
  • the injection solution further contains 0.3-0.8 g of sodium bisulfite per 1000 ml.
  • the injection solution further contains 0.5 g of sodium bisulfite per 1000 ml.
  • the injection also contains Na + of 80 mmol / L or less.
  • the injection solution further contains Cl -of 80 mmol / L or less.
  • the injection solution uses glacial acetic acid to adjust the pH value to 5.5-7.0.
  • the compound amino acid vitamin injection of the present invention is designed for the characteristics of energy metabolism of patients during perioperative anesthesia. It is designed to have specific amino acid components and ratios, and the addition of B vitamins, each component has a comprehensive effect, which can significantly inhibit catabolism and promote Anabolic, heat-generating insulation, improving the body's material energy metabolism and immune function, speeding up patient recovery after surgery.
  • the compound amino acid vitamin injection of the present invention meets the characteristics of material energy metabolism of patients during perioperative anesthesia, has high utilization rate and good clinical effect.
  • the invention is safe and efficient, and can be used in the whole process before, during and after surgery.
  • the present invention refers to changes in stress, immunity, metabolism, etc. during the perioperative anesthesia of the human body, and uses innovative formulas to respond to the concept of accelerated rehabilitation surgery, which inhibits catabolism, promotes anabolic metabolism, generates heat and heat, and improves body energy metabolism and Immune function for the purpose of accelerating recovery.
  • Branched-chain amino acids are essential amino acids, which are involved in sugar, fat, protein metabolism and energy balance through various pathways, and can improve amino acid metabolism disorders.
  • glutamine and alanine account for about 70%
  • branched chain amino acids are involved in de novo synthesis of glutamine and alanine. If the supplement is insufficient, protein synthesis and metabolism will be seriously affected.
  • B vitamins are directly involved in material energy metabolism.
  • vitamin B6 is involved in amino acid metabolism such as transamination, decarboxylation, side chain cleavage, dehydration, and transsulfidation. Supplementation can promote the use of amino acids.
  • Arginine has better nitrogen-saving effect and enhanced immune effect.
  • Amino acids in the other components of the injection play a balance and supplementary role.
  • Compound amino acid vitamin injection includes: L-leucine: 20.6g, L-isoleucine: 12.2g, L-valine: 15.2g, L-alanyl-L-glutamine : 25g, L-threonine: 2g, L-lysine (acetate): 3.8g, L-methionine: 3g, L-phenylalanine: 2.8g, L-tryptophan: 1g, L -Arginine: 12g, L-histidine: 2.4g, vitamin B6: 10mg, sodium bisulfite 0.5g, adjust the pH to 5.5-6.5 with glacial acetic acid, and add water for injection to a total of 1000ml.
  • Method of use Intravenous infusion at 4-8kJ ⁇ kg -1 ⁇ h -1 during the operation, and 1.2-2.0g / kg infusion per day after the operation.
  • L-leucine 40g, L-isoleucine: 30g, L-valine: 30g, L-alanyl-L-glutamine: 10g, L-threonine: 5g, L-lysine Amino acid (acetate): 5g, L-methionine: 2g, L-phenylalanine: 3g, L-tryptophan: 0.5g, L-arginine: 5g, L-histidine: 1g, Vitamin B6: 1mg, vitamin B1: 1mg, vitamin B12: 100 ⁇ g, sodium bisulfite 0.3g, Na + 10mmol / L, Cl - 10mmol / L, adjust the pH to 5.5-7.0 with glacial acetic acid, and add water for injection to the total The amount is 1000ml. Method of use: Intravenous infusion at 4-8kJ ⁇ kg -1 ⁇ h -1 during the operation, and 1.2-2.0g / kg infusion per day after the operation.
  • L-leucine 5g, L-isoleucine: 2g, L-valine: 2g, L-alanyl-L-glutamine: 5g, L-threonine: 1g, L-lysine Amino acid (acetate): 1g, L-methionine: 1g, L-phenylalanine: 1g, L-tryptophan: 8g, L-arginine: 30g, L-histidine: 10g, vitamins B6: 8mg, vitamin B1: 10mg, vitamin B12: 100 ⁇ g, sodium bisulfite 0.8g, Na + 80mmol / L, Cl - 80mmol / L, adjust the pH to 5.5-7.0 with glacial acetic acid, and add water for injection to the total 1000ml.
  • Method of use Intravenous infusion at 4-8kJ ⁇ kg -1 ⁇ h -1 during operation, and 1.2-2.0g / kg infusion per day after operation.
  • L-leucine 5g, L-isoleucine: 10g, L-valine: 2g, L-alanyl-L-glutamine: 90g, L-threonine: 1g, L-lysine Amino acid (acetate): 10g, L-methionine: 1g, L-phenylalanine: 10g, L-tryptophan: 0.5g, L-arginine: 30g, L-histidine: 1g, Vitamin B6: 100mg, Vitamin B1: 50mg, Vitamin B12: 100 ⁇ g, sodium bisulfite 0.3g, Na + 80mmol / L, Cl - 80mmol / L, adjust the pH to 5.5-7.0 with glacial acetic acid, and add water for injection to the total The amount is 1000ml. Method of use: Intravenous infusion at 4-8kJ ⁇ kg -1 ⁇ h -1 during the operation, and 1.2-2.0g / kg infusion per day after the operation.
  • L-leucine 40g, L-isoleucine: 2g, L-valine: 30g, L-alanyl-L-glutamine: 5g, L-threonine: 5g, L-lysine Amino acid (acetate): 1g, L-methionine: 12g, L-phenylalanine: 1g, L-tryptophan: 8g, L-arginine: 2g, L-histidine: 10g, vitamins B6: 10mg, vitamin B1: 10mg, vitamin B12: 100 ⁇ g, sodium bisulfite 0.8g, Na + 10mmol / L, Cl - 10mmol / L, adjust the pH to 5.5-7.0 with glacial acetic acid, and add water for injection to the total 1000ml.
  • Method of use Intravenous infusion at 4-8kJ ⁇ kg -1 ⁇ h -1 during the operation, and 1.2-2.0g / kg infusion per day after the operation.
  • L-leucine 30g, L-isoleucine: 20g, L-valine: 20g, L-alanyl-L-glutamine: 40g, L-threonine: 4g, L-lysine Amino acid (acetate): 8g, L-methionine: 10g, L-phenylalanine: 8g, L-tryptophan: 6g, L-arginine: 20g, L-histidine: 8g, vitamins B6: 2mg, vitamin B1: 4mg, vitamin B12: 40 ⁇ g, sodium bisulfite 0.6g, Na + 60mmol / L, Cl - 60mmol / L, adjust the pH to 5.5-7.0 with glacial acetic acid, and add water for injection to the total 1000ml.
  • Method of use Intravenous infusion at 4-8kJ ⁇ kg -1 ⁇ h -1 during operation, and 1.2-2.0g / kg infusion per day after operation.
  • the perioperative anesthesia patients' energy storage substances (glycogen, protein, fat) are mobilized to provide substrates for energy supply, tissue repair, and synthesis of new proteins, etc., and continue to the rehabilitation period, resulting in strong catabolism, Skeletal muscles are wasted, urine nitrogen is increased, negative nitrogen balance is produced, and the body's inflammation and immune response are prone to imbalance.
  • proteins due to central and peripheral insulin resistance, and free fatty acids and ketone bodies produced by lipolysis, proteins (amino acids) are safe and effective substances for energy supply during perioperative anesthesia.
  • Branched-chain amino acids are essential amino acids. They participate in sugar, fat, protein metabolism and energy balance through a variety of pathways, and can improve amino acid metabolism disorders.
  • glutamine and alanine account for about 70%, and branched chain amino acids are involved in de novo synthesis of glutamine and alanine. If the supplement is insufficient, protein synthesis and metabolism will be seriously affected.
  • B vitamins are directly involved in material energy metabolism.
  • vitamin B6 participates in amino acid metabolism such as transamination, decarboxylation, side chain cleavage, dehydration, and transsulfidation. Supplementation can promote the use of amino acids.
  • Arginine has a better nitrogen-saving effect and enhances the immune effect.
  • the compound amino acid vitamin injection of the present invention is designed to meet the energy metabolism needs of perioperative anesthesia patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une solution d'injection de vitamine d'acide aminé composée et son utilisation. La solution d'injection de vitamine d'acide aminé composée comprend pour 1000 mL : 5 à 40 g de L-leucine, 2 à 30 g de L-isoleucine, 2 à 30 g de L-valine, 5 à 90 g de L-alanyl-L-glutamine, 1 à 5 g de L-thréonine, 1-10 g de L-lysine, 1 à 12 g de L-méthionine, 1 à 10 g de L-phénylalanine, 0,5 à 8 g de L-tryptophane, 2 à 30 g de L-arginine, 1 à 10 g de L-histidine, 1 à 100 mg de vitamine B6, 0 à 50 mg de vitamine B1, et 0 à 100 μg de vitamine B12. La présente invention concerne des changements de stress, d'immunisation, de métabolisme ou similaires dans une période périopératoire humaine, et permet d'inhiber le catabolisme, de favoriser l'anabolisme, de produire de la chaleur et de maintenir la chaleur, d'améliorer le métabolisme énergétique des substances et l'immunité du corps, et d'aider à la rééducation.
PCT/CN2019/087884 2018-06-29 2019-05-22 Solution d'injection de vitamine d'acide aminé composée et son utilisation WO2020001203A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810694065.9A CN108721596B (zh) 2018-06-29 2018-06-29 一种复方氨基酸维生素注射液及其应用
CN201810694065.9 2018-06-29

Publications (1)

Publication Number Publication Date
WO2020001203A1 true WO2020001203A1 (fr) 2020-01-02

Family

ID=63931134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/087884 WO2020001203A1 (fr) 2018-06-29 2019-05-22 Solution d'injection de vitamine d'acide aminé composée et son utilisation

Country Status (2)

Country Link
CN (1) CN108721596B (fr)
WO (1) WO2020001203A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113143853A (zh) * 2021-03-30 2021-07-23 赜誉(上海)生物科技有限公司 一种高效型棉多酚类中药提取物水溶液制剂的制备方法
CN114601846A (zh) * 2020-12-03 2022-06-10 河北科星药业有限公司 一种畜用复合维生素氨基酸注射液及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108721596B (zh) * 2018-06-29 2021-09-21 复旦大学附属中山医院 一种复方氨基酸维生素注射液及其应用
CN110404048A (zh) * 2019-09-05 2019-11-05 复旦大学附属中山医院 一种复方氨基酸双肽注射液及其制备方法和应用
CN114469941A (zh) * 2020-10-27 2022-05-13 河北科星药业有限公司 用于畜疾病防治的复合氨基酸注射液及其制备方法和应用
TWI836188B (zh) * 2021-02-20 2024-03-21 德國商生命生物技術有限責任公司 用於治療壓力、心理創傷或身體疲勞之成分組合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401785A (zh) * 2008-10-22 2009-04-08 广东利泰药业有限公司 氨基酸注射液及其制备方法
CN108721596A (zh) * 2018-06-29 2018-11-02 复旦大学附属中山医院 一种复方氨基酸维生素注射液及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144533C (zh) * 1998-03-25 2004-04-07 广西大学 复合氨基酸钙盐补钙剂及其生产方法
JP5177785B2 (ja) * 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
CN101332209B (zh) * 2007-06-25 2010-12-08 三菱制药（广州）有限公司 治疗肝性脑病的复方氨基酸注射液
CN101332195B (zh) * 2007-06-25 2011-05-11 三菱制药（广州）有限公司 复方支链氨基酸注射液
CN102429902B (zh) * 2011-09-09 2013-03-20 海南灵康制药有限公司 一种丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN103071145B (zh) * 2011-10-25 2014-06-25 杭州长典医药科技有限公司 N(2)-l-丙氨酰-l-谷氨酰胺/复方氨基酸注射液（18aa-v）药物组合制剂
CN103315997A (zh) * 2012-03-19 2013-09-25 郑飞雄 一种含18种氨基酸的药物组合物
CN102631665B (zh) * 2012-04-19 2013-09-25 海南灵康制药有限公司 一种丙氨酰谷氨酰胺注射液和复方氨基酸注射液的药物组合物
CN102988359B (zh) * 2012-12-13 2014-06-11 天津金耀集团有限公司 复方氨基酸注射液（18aa-i）组合物
CN102973557A (zh) * 2012-12-13 2013-03-20 天津金耀集团有限公司 复方氨基酸注射液（18aa-iii）组合物
CN104013619A (zh) * 2014-05-27 2014-09-03 刘力 复方氨基酸注射液18aa-v的药物组合物和用途
CN104940195A (zh) * 2015-05-14 2015-09-30 海南圣欣医药科技有限公司 一种含丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN106491601A (zh) * 2016-10-24 2017-03-15 安徽富邦药业有限公司 一种复方氨基酸注射液及其制备方法
CN108210879A (zh) * 2016-12-15 2018-06-29 张海峰 一种治疗急性颅脑出血的药物组合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401785A (zh) * 2008-10-22 2009-04-08 广东利泰药业有限公司 氨基酸注射液及其制备方法
CN108721596A (zh) * 2018-06-29 2018-11-02 复旦大学附属中山医院 一种复方氨基酸维生素注射液及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENG, FUQIANG ET AL.: "Physicians' Desk Drug Reference ( Chinese Patent Medicine; Chemical Medicine)", NUTRACEUTICALS, 31 March 2012 (2012-03-31) *
ZHENG, CHUNYING: "Pay Attention to Rational Clinical Application of Compound Amino Acid Injection", MEDICAL JOURNAL OF CHINESE PEOPLE'S HEALTH, vol. 20, no. 20, 30 October 2008 (2008-10-30) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114601846A (zh) * 2020-12-03 2022-06-10 河北科星药业有限公司 一种畜用复合维生素氨基酸注射液及其制备方法和应用
CN113143853A (zh) * 2021-03-30 2021-07-23 赜誉(上海)生物科技有限公司 一种高效型棉多酚类中药提取物水溶液制剂的制备方法

Also Published As

Publication number Publication date
CN108721596B (zh) 2021-09-21
CN108721596A (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
WO2020001203A1 (fr) Solution d'injection de vitamine d'acide aminé composée et son utilisation
US7645796B2 (en) Amino acid composition promoting collagen synthesis
US5462924A (en) Product containing growth factor and glutamine and use of growth factor for the treatment of intestinal mucosa
KR102057555B1 (ko) 신부전 환자를 치료하기 위한 카복실산 혼합물
JPS643847B2 (fr)
JPS61247354A (ja) 栄養素組成物
JPS60255722A (ja) 糖尿病用アミノ酸輸液
US20090306209A1 (en) Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
RU2009126763A (ru) Лечение общих расстройств развития
JPH01301619A (ja) 癌用アミノ酸製剤
JP2599593B2 (ja) 腎不全用アミノ酸輸液
BRPI1011103B1 (pt) Composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l- aspártico
JPH0463049B2 (fr)
JPH03204814A (ja) 腎不全用経口アミノ酸製剤
JPH08175987A (ja) 経口経腸栄養組成物
WO2019204633A1 (fr) Compositions et procédés d'utilisation correspondants destinés à favoriser la croissance et la fonction musculaires
TW201210587A (en) Medicinal agent for prevention and/or treatment of hepatocellular carcinoma
EP2504006B1 (fr) Compositions comprenant des acides aminés pour le traitement de la bronchopneumopathie chronique obstructive
CA2113279A1 (fr) Utilisation de l'alpha-cetoglutarate
JPH02306914A (ja) 癌用アミノ酸製剤
JPH09110686A (ja) マクロファージ一酸化窒素産生亢進剤
JPH04159219A (ja) 腎不全用経口アミノ酸製剤
Pavlickova Aimova et al. The importance and dosage of amino acids in nutritional support of various pathological conditions in ICU patients
WO1995022967A1 (fr) Stimulateur de l'activite analgesique
JP3429327B2 (ja) 癌用アミノ酸輸液剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19827209

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19827209

Country of ref document: EP

Kind code of ref document: A1